Coming soon · Sunday 25 October · 13:00 CET
SCLC Symposium at ESMO 2026: From IO-Standards to the TCE Era
SymposiumRecording to follow2 CME credits · EACCME & SSMO
Programme & faculty
The Role of Immune Checkpoint Blockade in SCLC: Achievements & Limitations
Martin ReckGermany
Redefining the Standards: The Era of DLL3 T-Cell Engagers
Solange PetersSwitzerland
Practical Management of DLL3 T-Cell Engagers
Giannis MountziosGreece
The Evolving Algorithm: Sequencing Innovative Strategies
Noemí ReguartSpain
Event details
Main Sponsor
Co-Sponsor
This session was supported by the partner(s) shown above.
SCLC Symposium at ESMO 2026: From IO-Standards to the TCE Era
Continue With
Related Topics
Jul
05
2026
Targeted Therapies in NSCLC
Jul
05
2026
The International Lung Cancer Summit 2026
The International Lung Cancer Summit returns on 13 November 2026 – on site in Lausanne and streamed online. A one-day programme of practice-changing lung cancer debates, chaired by Solange Peters and Alfredo ...
Apr
15
2026
TARGETED THERAPIES
Targeted Therapies in Metastatic NSCLC: Reshaping First-Line Choice
Five next-generation TKIs have rewritten first-line choice in driver-positive metastatic NSCLC. This update distils which biomarker matters, when CNS coverage drives the pick, and where the field is heading ...
Mar
22
2026
ADCs
ADCs in Small Cell Lung Cancer: An Emerging Class
Antibody-drug conjugates are arriving in SCLC after a decade of failed cytotoxics. Three platforms — DLL3, B7-H3, and SEZ6 — now have phase-2 readouts. This update...
Dec
18
2025
2025 Approvals & Highlights
1 h 49 min
Sep
26
2025
RESHAPING APPROACHES IN SCLC WITH THE LATEST ADVANCES IN LS- AND ES-DISEASE
34 min
Sep
26
2025
LATEST OPTIONS FOR NON-ONCOGENE ADDICTED METASTATIC NSCLC IN FRONTLINE AND BEYOND
32 min
Sep
26
2025
THE ROLE OF IO ADDED TO CHEMORADIATION IN UNRESECTABLE STAGE III NSCLC
28 min
Sep
26
2025
TAILORING IO IN RES. NSCLC: PERSONALIZED APPROACHES FOR IMPROVED OUTCOMES
36 min
Sep
26
2025
SPONSORED INTERVIEW
Latest Advances in Frontline EGFR+ NSCLC
14 min
Sep
26
2025
INDUSTRY SYMPOSIUM
UNLOCKING NEW POTENTIALS IN EGFR-MUTANT NSCLC
30 min
Sep
26
2025
THE ADC REVOLUTION IN LUNG CANCER: NEW TARGETS, NEW OPPORTUNITIES
27 min
Sep
26
2025
DEBATE: WHICH IS THE BETTER CHOICE IN EGFR+ METASTATIC NSCLC?
31 min
Sep
26
2025
ACTIONABLE GENOMIC ALTERATIONS – INCLUDING HER2 AND MET
26 min
Sep
26
2025
TARGETING EGFR AND ALK IN NSCLC
26 min
Sep
26
2025
CUTTING-EDGE DIAGNOSTIC TECHNIQUES AND EMERGING BIOMARKERS
24 min
Sep
26
2025
Open Discussion on Patient Cases
22 min
Jul
10
2025
Targeted Therapies in NSCLC
1h 30 min
Jun
25
2025
Immunotherapies in NSCLC
1h 47 min
Jun
17
2025
Small Cell Lung Cancer
1h 35 min